Regulatory 2022-02-10 | Quarterly Report Q4 2021: Strong data for Orviglance vs. a gadolinium contrast agent PDF Presentation Webcast Excel
Regulatory 2021-02-16 | Quarterly Report Q4 2020: Mangoral shows high diagnostic value in new study PDF Presentation Webcast Excel
Regulatory 2020-02-14 | 2019 year-end financial report: Sites opened for recruitment to the pivotal Phase III study SPARKLE PDF Presentation Webcast Excel
Regulatory 2019-08-22 | Phase III study of Mangoral to start in H2-2019 PDF Presentation Webcast Excel
